ANI Pharmaceuticals’ Earnings Call Contradictions: Sales Force Growth Timeline, Re-Verification Status Don’t Match

Date of Call: Aug 7, 2026

Financials Results

• Revenue: $266 million, up 26% YOY
• EPS: $2.21 non-GAAP diluted EPS, up from $1.80 prior year
• Gross Margin: 62.6%, down approximately 230 basis points YOY

Guidance:

• Total net revenue for 2026 expected to be $1.08 billion to $1.14 billion, representing 6% YOY growth at the midpoint.
• Adjusted non-GAAP EBITDA for 2026 expected to be $285 million to $300 million.
• Cortofan gel net revenue guidance for 2026 modestly revised to $520 million to $540 million.
• Alluvion net revenue guidance reaffirmed at $78 million to $83 million.
• Adjusted non-GAAP diluted EPS expected to be $9.19 to $9.69.
• Expect continued strong momentum in existing specialties and the gout expansion, with Q3 and Q4 EBITDA growth expected to accelerate.

Business Commentary:

Revenue Growth and Rare Disease Focus:

• ANI Pharmaceuticals reported record second quarter, 2026 revenues of $266 million, up 26% year-over-year.
• The growth was driven by a focus on rare disease, particularly strong performance in Cortofan gel and Elluvian, with Cortofan gel net revenues increasing 43% year-over-year.

Sales Force Expansion and Market Penetration:

• The company expanded its sales force by 50% to approximately 180 representatives, focusing on acute gouty arthritis flares.
• This expansion is expected to drive significant growth, with strong demand indicated by over 95% of reps generating multiple new cases.

Generics Revenue and Strategic Execution:

• ANI's generics revenue was $99.1 million, up 10% year-over-year, with the launch of 12 generic products in 2026.
• The growth in generics is attributed to superior R&D capabilities and operational execution, positioning the company as a leader in the U.S. generics market.

Guidance and Growth Projections:

• The company revised its Cortofan gel revenue guidance for 2026 to between $520 million and $540 million.
• This revision reflects the strong growth trajectory and market potential, supported by momentum in existing specialties and the new gout expansion.

Financial Performance and Leverage:

• ANI achieved an adjusted non-GAAP EBITDA of $71.6 million, a 32% year-over-year increase.
• The improvement was driven by operational outperformance and cost management, with a focus on delivering profitability and revenue growth.

Sentiment Analysis:

Overall Tone: Positive

• Management highlighted 'record second quarter revenues,' 'strong demand expansion,' and 'very positive early feedback' from the gout launch. They are 'well positioned to drive meaningful growth' and 'confident in achieving our 2026 financial guidance.' The tone is optimistic about the transformation into a rare disease company and the large addressable market opportunities.

Q&A:

• Question from Vommel Devon (Guggenheim Partners): Can you give a little bit more detail in terms of what you've been seeing so far in terms of the gout uptake? Also, trying to get a sense of how penetrated the current indications are.
  Response: Leading indicators from the gout expansion are very positive, with over 95% of reps generating multiple new cases and over a third of prescribers initiating two or more cases. The existing specialties penetration is very low, indicating a huge opportunity for multi-year growth.

• Question from Glenn Sant'Angelo (Barclays): How have prior authorization and re-verification issues progressed, and is that playing a role in the guidance revision? Also, there's a disconnect between IQVIA data and reported revenues.
  Response: Insurance re-verification issues are behind us and had no meaningful impact on Q2 revenues. The guidance revision is based on the actual first-half performance, not new headwinds. IQVIA data has volatility and is not always aligned with quarterly revenues.

• Question from Dennis (Jeffries): What factors drove the guidance revision lower by about $30 million? Also, what gives confidence in the Q4 step-up?
  Response: The revision accounts for the actual first-half performance, but expectations for the back half are largely intact. Confidence in Q4 comes from the full deployment of the gout expansion (3x larger than last year's) and the strong momentum in existing specialties.

• Question from David Amselem (Piper Sandler): Can you clarify what percentage of 'cases initiated' become prescriptions? What is the typical fill time? Will further Salesforce expansion be needed for operating leverage?
  Response: 'Cases initiated' means prescriptions written. Fill time varies but has been consistently improved over five years. Full operating leverage from the 2026 sales force investment is expected in 2027.

• Question from Ekaterina Nezkova (J.P. Morgan): What percent of Q1 volumes were recovered in Q2 versus permanently lost? Should we expect similar issues in 2027? Any trends in vial usage per patient?
  Response: Most patients from the Q1 re-verification were recovered, though some shifted in timing; this is consistent with prior years and no additional impact is expected. Vial usage per patient varies by indication but no significant shift is noted.

• Question from Gary Knockman (Canaccord Genuity): What portion of Cortofan volume was from gout in Q2? Is revenue per patient lower in gout? Any anticipated gross-to-net pressure?
  Response: Gout contribution in Q2 was limited as expected, with a ramp anticipated in Q3/Q4. Vial usage per patient is lower in gout, but there are many more patients. No new information on gross-to-net pressure.

• Question from Thomas (Leerink Partners): Are there differences in engagement with podiatrists/PCPs versus the base business? How much demand came from the pilot territories?
  Response: Engagement with podiatrists and PCPs is consistent with past experiences. Demand momentum is broad across all reps in the gout expansion, not limited to pilot territories.

• Question from Brennan Folks (HC Wainwright): Is Cortofan use declining in existing specialties? What drove the guidance change, and are prior issues resolved?
  Response: No slowdown is seen in existing specialties; momentum remains strong (e.g., ophthalmology volumes doubled YOY). The guidance revision reflects the actual first-half performance, not new headwinds, and prior issues are resolved.

Contradiction Point 1

Timeline and Confidence for Sales Force Expansion Impact

Conflicting statements on when the sales force expansion will drive significant growth.

Dennis (Jeffries) - Dennis (Jeffries)

2026Q2: The 3× larger sales force expansion... will be fully operational for three months in Q3 and a full quarter in Q4, driving significant growth. - [Chris Mutz](Senior Vice President, Head of Commercial)

What factors led to the $30M reduction in full-year Cortofan gel revenue guidance, and what supports the Q4 step-up? - Dennis Ding (Jefferies)

2026Q1: The expansion aims to reach the 285,000-patient addressable market... The addition of 64 new sales reps is an investment... The bulk of growth still coming from the core portfolio. - [Nikhil Lalwani](Responder)

Contradiction Point 2

Status and Impact of Insurance Re-Verification Issues

Contradiction on whether re-verification issues are fully resolved or still pose a future risk.

What were the main drivers of earnings growth this quarter? - Glenn Sant’Angelo (Barclays)

2026Q2: The re-verification issue is resolved and behind us; it had no material impact on achieving the 56% sequential growth in Q2. - [Chris Mutz](Senior Vice President, Head of Commercial)

How have prior authorization/re-verification issues progressed, given the apparent disconnect between reported performance and IQVIA data? - Les Szalankiewicz (Truist)

2026Q1: The re-verification headwind was largely in the first half of Q1. The backlog has been cleared, and momentum accelerated. For the end of 2026/early 2027, the company is collaborating with physician offices to implement initiatives to smooth the re-verification process... - [Nikhil Lalwani](Responder)

Contradiction Point 3

Growth Contribution and Uptake from New Indications (Gout)

Inconsistency on the current growth contribution from the gout indication.

Gary Knauf (Canaccord Genuity) - Gary Knauf (Canaccord Genuity)

2026Q2: Gout currently represents ~18% of total Cortofan volume. - [Chris Mutz](Senior Vice President, Head of Commercial)

What was the Q2 contribution from gout, how does vial usage differ in gout versus other indications, and is there any gross-to-net pressure? - Brandon Folkes (H.C. Wainwright)

2026Q1: Prescribing for acute gouty arthritis flares represents 18% of Cortrophin volumes (mostly from rheumatology/nephrology). - [Nikhil Lalwani](Responder)

Contradiction Point 4

Operating Leverage Expectations

Contradiction on the year when full operating leverage will be achieved.

David Amselem (Piper Sandler) - David Amselem (Piper Sandler)

2026Q2: The 2026 sales force expansion will yield full operating leverage (revenue growth > expense growth) in 2027. - [Chris Mutz](Senior Vice President, Head of Commercial)

Clarify what “new cases initiated” means in terms of prescriptions, the typical fill time, and whether further sales force expansion is needed for operating leverage? - David Amsellem (Piper Sandler & Co.)

2025Q4: Despite a ~$50M SG&A increase in 2026 guidance, EBITDA margin percentage is maintained, with full operating leverage expected to kick in more strongly in 2027 as the new sales force reaches full productivity. - [Nikhil Lalwani](CEO)

Contradiction Point 5

Sales Force Expansion ROI and Future Plans

Contradiction on whether sales force expansion is a high ROI investment yielding leverage or requires careful, selective evaluation.

David Amselem (Piper Sandler) - David Amselem (Piper Sandler)

2026Q2: The 2026 sales force expansion will yield full operating leverage (revenue growth > expense growth) in 2027. - [Chris Mutz](Senior Vice President, Head of Commercial)

Can you clarify what "new cases initiated" means in terms of prescriptions, what the typical fill time is, and whether further sales force expansion will be needed for operating leverage? - Gary Nachman (Raymond James & Associates, Inc.)

2025Q3: The expansion of the sales force in Q1 was a high ROI investment, and the company will continue to evaluate such opportunities based on ROI metrics. - [Nikhil Lalwani](CEO)